Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,shortLongTermDebt,deferredLongTermLiab,otherAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceHint,regularMarketChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,priceEpsCurrentYear,currency,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,shortName,exchangeDataDelayedBy,market,marketState,epsTrailingTwelveMonths,epsForward,epsCurrentYear,twoHundredDayAverageChangePercent,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,DCTH,15159000.0,6472400,3497000,,-6430000,,-6430000,3288000,334000,-6451000,-6451000,,-40000,,,,0,536000,6987000,202000,21000,,-6430000,-6430000,423660000.0,9758000.0,15159000.0,509000.0,24917000.0,74000.0,151000.0,-408504000.0,1754000.0,-71000.0,19274000.0,5741000.0,-71000.0,2011000.0,22906000.0,75000.0,2000000.0,1221000.0,1224000.0,,,,-809000.0,-79000.0,17000.0,-1458000.0,17000.0,-7225000.0,-61000.0,-7102000.0,39000.0,-112000.0,1000.0,1667000.0,-79000.0,,,17165000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,50016,1.5200005,0.18357494,8.28 - 25.18,-15.38,-0.61080223,8.28,25.18,1577145600,1620736200,1636464600,1636983000,3.2,9.528611,0.271389,0.028481485,12.708732,-2.9087315,63429520,-2.7683616,2,-1.9999981,3.0625,15,America/New_York,EDT,-14400000,9.59 - 9.93,10.0,9.5,9.95,14,14,finmb_598622,NasdaqCM,"Delcath Systems, Inc.",USD,57409,-2.413793,USD,False,False,9.8,1630503657,-0.19999981,9.93,9.93,9.59,1340,NCM,"Delcath Systems, Inc.",0,us_market,REGULAR,-5.128,-3.54,-4.06,-0.22887662,0.54,,,25.18,8.28,9.53,12.71,57.41k,50.02k,6.47M,,6.31M,1.79%,30.16%,442.77k,8.67,6.08%,6.02%,464.72k,,,,,,0.00%,"Dec 23, 2019",,1:700,"Dec 23, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,324.39%",-69.27%,-220.44%,1.9M,0.34,41.40%,1.01M,-24.98M,-25.2M,-5.13,,19.27M,2.62,2.65M,17.48,3.99,3.20,-21.45M,-12.12M,Value,10019,Healthcare,36,"Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.",New York,212 489 2100,NY,1609372800,United States,http://www.delcath.com,86400,1633 Broadway,212 489 2102,Medical Devices,22nd Floor Suite C
t-1,DCTH,20006000.0,6472400,3707000,,-6747000,,-6747000,3296000,276000,-6727000,-6727000,,-41000,,,,0,388000,7115000,112000,-20000,,-6747000,-6747000,422027000.0,12309000.0,20006000.0,502000.0,32315000.0,63000.0,50000.0,-402074000.0,1856000.0,-10000.0,26600000.0,10096000.0,-10000.0,2112000.0,30203000.0,75000.0,,1109000.0,1234000.0,2000000.0,,,-75000.0,-9000.0,2376000.0,302000.0,2376000.0,-2106000.0,94000.0,-4567000.0,39000.0,-254000.0,-18000.0,2186000.0,-9000.0,,,20107000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,50016,1.5200005,0.18357494,8.28 - 25.18,-15.38,-0.61080223,8.28,25.18,1577145600,1620736200,1636464600,1636983000,3.2,9.528611,0.271389,0.028481485,12.708732,-2.9087315,63429520,-2.7683616,2,-1.9999981,3.0625,15,America/New_York,EDT,-14400000,9.59 - 9.93,10.0,9.5,9.95,14,14,finmb_598622,NasdaqCM,"Delcath Systems, Inc.",USD,57409,-2.413793,USD,False,False,9.8,1630503657,-0.19999981,9.93,9.93,9.59,1340,NCM,"Delcath Systems, Inc.",0,us_market,REGULAR,-5.128,-3.54,-4.06,-0.22887662,0.54,,,25.18,8.28,9.53,12.71,57.41k,50.02k,6.47M,,6.31M,1.79%,30.16%,442.77k,8.67,6.08%,6.02%,464.72k,,,,,,0.00%,"Dec 23, 2019",,1:700,"Dec 23, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,324.39%",-69.27%,-220.44%,1.9M,0.34,41.40%,1.01M,-24.98M,-25.2M,-5.13,,19.27M,2.62,2.65M,17.48,3.99,3.20,-21.45M,-12.12M,Value,10019,Healthcare,36,"Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.",New York,212 489 2100,NY,1609372800,United States,http://www.delcath.com,86400,1633 Broadway,212 489 2102,Medical Devices,22nd Floor Suite C
t-2,DCTH,22078000.0,6472400,2744000,,-7029000,,-7029000,4537000,301000,-6980000,-6980000,,-21000,,,,0,507000,7487000,206000,-49000,,-7029000,-7029000,417449000.0,12557000.0,22078000.0,525000.0,34635000.0,60000.0,181000.0,-395327000.0,2072000.0,-104000.0,28575000.0,10035000.0,-104000.0,2297000.0,32338000.0,57000.0,,855000.0,1774000.0,2000000.0,,,-619000.0,-74000.0,22443000.0,-76000.0,26963000.0,17676000.0,-93000.0,-4600000.0,-425000.0,-16000.0,46000.0,3519000.0,-74000.0,-4520000.0,,22303000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,50016,1.5200005,0.18357494,8.28 - 25.18,-15.38,-0.61080223,8.28,25.18,1577145600,1620736200,1636464600,1636983000,3.2,9.528611,0.271389,0.028481485,12.708732,-2.9087315,63429520,-2.7683616,2,-1.9999981,3.0625,15,America/New_York,EDT,-14400000,9.59 - 9.93,10.0,9.5,9.95,14,14,finmb_598622,NasdaqCM,"Delcath Systems, Inc.",USD,57409,-2.413793,USD,False,False,9.8,1630503657,-0.19999981,9.93,9.93,9.59,1340,NCM,"Delcath Systems, Inc.",0,us_market,REGULAR,-5.128,-3.54,-4.06,-0.22887662,0.54,,,25.18,8.28,9.53,12.71,57.41k,50.02k,6.47M,,6.31M,1.79%,30.16%,442.77k,8.67,6.08%,6.02%,464.72k,,,,,,0.00%,"Dec 23, 2019",,1:700,"Dec 23, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,324.39%",-69.27%,-220.44%,1.9M,0.34,41.40%,1.01M,-24.98M,-25.2M,-5.13,,19.27M,2.62,2.65M,17.48,3.99,3.20,-21.45M,-12.12M,Value,10019,Healthcare,36,"Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.",New York,212 489 2100,NY,1609372800,United States,http://www.delcath.com,86400,1633 Broadway,212 489 2102,Medical Devices,22nd Floor Suite C
t-3,DCTH,3276000.0,6472400,3260000,,-4991000,,-4991000,1998000,278000,-4980000,-4980000,,-44000,,,,0,466000,5446000,188000,-11000,,-4991000,-4991000,391545000.0,13289000.0,3276000.0,501000.0,16565000.0,40000.0,181000.0,-388298000.0,2103000.0,-11000.0,10899000.0,10644000.0,-11000.0,2415000.0,13882000.0,103000.0,,839000.0,1502000.0,2000000.0,268000.0,268000.0,165000.0,-487000.0,663000.0,-289000.0,670000.0,-5112000.0,-102000.0,-5186000.0,190000.0,-115000.0,43000.0,-189000.0,-487000.0,-4000.0,-3000.0,3238000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,50016,1.5200005,0.18357494,8.28 - 25.18,-15.38,-0.61080223,8.28,25.18,1577145600,1620736200,1636464600,1636983000,3.2,9.528611,0.271389,0.028481485,12.708732,-2.9087315,63429520,-2.7683616,2,-1.9999981,3.0625,15,America/New_York,EDT,-14400000,9.59 - 9.93,10.0,9.5,9.95,14,14,finmb_598622,NasdaqCM,"Delcath Systems, Inc.",USD,57409,-2.413793,USD,False,False,9.8,1630503657,-0.19999981,9.93,9.93,9.59,1340,NCM,"Delcath Systems, Inc.",0,us_market,REGULAR,-5.128,-3.54,-4.06,-0.22887662,0.54,,,25.18,8.28,9.53,12.71,57.41k,50.02k,6.47M,,6.31M,1.79%,30.16%,442.77k,8.67,6.08%,6.02%,464.72k,,,,,,0.00%,"Dec 23, 2019",,1:700,"Dec 23, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,324.39%",-69.27%,-220.44%,1.9M,0.34,41.40%,1.01M,-24.98M,-25.2M,-5.13,,19.27M,2.62,2.65M,17.48,3.99,3.20,-21.45M,-12.12M,Value,10019,Healthcare,36,"Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.",New York,212 489 2100,NY,1609372800,United States,http://www.delcath.com,86400,1633 Broadway,212 489 2102,Medical Devices,22nd Floor Suite C
